Skip to main content

Table 2 Correlation of NAP1L1 expression with clinicopathological characteristics of patients with Breast cancer

From: NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth

Characteristics

n

NAP1L1 expression

High

Low

p

Age(year)

 < 50

43

15 (34.9%)

28 (65.1%)

0.067

 ≥ 50

54

10 (18.5%)

44 (81.5%)

Clinical stage

 I

8

1 (12.5%)

7 (87.5%)

0.025

 II

53

9 (17.0%)

44 (83.0%)

 III

36

15 (41.7%)

21 (58.3%)

Tumor scale

 ≤ 3 cm

53

13 (24.5%)

40 (75.5%)

0.758

 > 3 cm

44

12 (27.3%)

32 (72.7%)

Histological grade

 I

29

9 (31.0%)

20 (69.0%)

0.439

 II–III

68

16 (23.5%)

52 (76.5%)

Vital states

 Die

26

13 (50.0%)

13 (50.0%)

0.001

 Alive

71

12 (16.9%)

59 (83.1%)

ER

 Negative

36

12 (33.3%)

24 (66.7%)

0.191

 Positive

61

13 (21.3%)

48 (78.7%)

PR

 Negative

40

14 (35.0%)

26 (65.0%)

0.082

 Positive

57

11 (19.3%)

46 (80.7%)

HER2

 Negative

60

15 (25.0%)

45 (75.0%)

0.825

 Positive

37

10 (27.0%)

27 (73.0%)

Lymph metastasis

 No

32

6 (18.8%)

26 (81.2%)

0.267

 Yes

65

19 (29.2%)

46 (70.8%)